Trump endorsed Republican Representative Julia Letlow in an unusual attempt to unseat an incumbent senator, targeting Cassidy over his vote to convict Trump during his 2021 impeachment trial following the Jan. 6 attack on the U.S. Capitol.

In social media posts hours before voting began, Trump described Cassidy as “a disloyal disaster” and “a terrible guy,” while predicting the senator would be “CLOBBERED” in the primary. Trump praised Letlow as “a winner” who would remain loyal to his political agenda.

The contest also includes Louisiana State Treasurer John Fleming, a former congressman and longtime Trump ally. Under Louisiana election rules, a runoff election will be held June 27 if no candidate secures more than 50% of the vote.

The race is widely viewed as a referendum on Trump’s dominance within the Republican Party ahead of the 2026 midterm elections, particularly among conservatives who have challenged him on impeachment, public health policy or institutional governance.

Cassidy, a physician and chair of the Senate health committee, has faced sustained criticism from Trump-aligned Republicans over both his impeachment vote and his cautious stance toward Health Secretary Robert F. Kennedy Jr., whose confirmation Cassidy ultimately supported despite expressing concern over Kennedy’s vaccine views.

Trump recently blamed Cassidy for undermining the nomination of surgeon general candidate Casey Means after the senator publicly defended hepatitis B vaccinations for newborns, a position at odds with some vaccine skeptics allied with Kennedy.

Despite trailing Trump-backed enthusiasm in the state, Cassidy mounted an expensive and increasingly aggressive campaign in the final weeks of the race. According to advertising tracker AdImpact, Cassidy’s campaign and affiliated super PAC Louisiana Freedom Fund were projected to spend more than $21 million combined on advertising through May 16.

By comparison, Letlow’s campaign and the pro-Letlow Accountability Project super PAC were projected to spend roughly $10 million combined. Fleming’s campaign spending totaled approximately $1.5 million.
Cassidy and allied groups sought to portray Letlow as insufficiently conservative by highlighting her previous support for diversity, equity and inclusion initiatives during her tenure as a university administrator before entering Congress.

Political analysts said the contest had tightened in recent months despite Trump’s dominance in Louisiana, a state he carried comfortably in three presidential elections.

The election also unfolded amid voter confusion triggered by Louisiana’s delayed congressional primaries following a recent U.S. Supreme Court ruling affecting enforcement of portions of the Voting Rights Act tied to congressional district maps. State officials postponed House primaries to redraw district boundaries, while the Senate primary proceeded as scheduled.

Analysts said the scheduling changes could affect turnout patterns, particularly among less politically engaged voters.

Letlow entered the race only after securing Trump’s endorsement in January, despite earlier speculation about a possible candidacy. Her political rise followed the death of her husband, Luke Letlow, who died from COVID-19 complications in 2020 shortly after being elected to Congress but before taking office. She later won the seat in a special election and retained it in subsequent elections.

The U.S. Food and Drug Administration begins a new chapter in its drug evaluation and research division, focusing on ethics, transparency, and accelerated innovation in medical safety and approvals.

The U.S. Food and Drug Administration has announced a leadership transition within its Center for Drug Evaluation and Research.

This change marks a renewed focus on ethical governance, transparency, and the continued protection of public health across the nation.

The FDA remains a cornerstone of global drug safety and medical innovation.

With a commitment to upholding the highest professional and ethical standards, the agency’s leadership transition aims to enhance confidence in its policies and regulatory framework.

Officials reaffirmed their dedication to maintaining trust with the public, the medical community, and the pharmaceutical industry.

The Department of Health and Human Services emphasized that the change in leadership is part of its broader mission to ensure accountability and strengthen the FDA’s decision-making process.

By maintaining an environment of openness and collaboration, the FDA seeks to empower scientific teams to focus on evidence-based regulation.

The agency continues to oversee the approval and monitoring of over-the-counter and prescription medicines used by millions of Americans every day.

Industry experts say the leadership change offers an opportunity to refine the FDA’s innovative programs, including fast-track drug approvals and modernized testing standards.

These initiatives help bring critical treatments to patients faster while maintaining rigorous safety protocols.

The agency has also reaffirmed its commitment to transparency in communications and ensuring that every decision is rooted in solid scientific analysis.

Officials believe that this renewed emphasis on ethical leadership will help foster stronger relationships with healthcare providers and pharmaceutical innovators.

This transition comes at a time when global health agencies are undergoing modernization efforts to adapt to rapid scientific advances and the growing complexity of medical research.

The FDA is playing a crucial role in guiding this transformation by integrating advanced data analytics, artificial intelligence, and real-world evidence into its review processes.

The leadership reshuffle is expected to encourage smoother coordination among divisions, allowing for faster response times to emerging health challenges.

This includes addressing public health emergencies, approving breakthrough therapies, and ensuring access to affordable, high-quality medicines.

The agency also remains committed to collaboration with international health bodies to align regulatory standards and streamline global approvals.

Such cooperation strengthens confidence in the safety and effectiveness of U.S.-approved medical products worldwide.

Under the direction of Health Secretary Robert F. Kennedy Jr., the department has been actively working toward improving transparency and accountability across all U.S. health agencies.

These efforts are part of a larger vision to rebuild trust between health institutions and the public while encouraging innovation in life sciences.

Experts suggest that transitions like these can often energize an organization by bringing fresh perspectives and renewed focus to key priorities.

Stakeholders in the healthcare sector have welcomed the move as a step toward enhancing clarity, communication, and consistency within the regulatory ecosystem.

The FDA’s ability to balance innovation with public safety continues to make it one of the most respected institutions in the global health landscape.

With new leadership, the agency aims to strengthen its role as a protector of public well-being while embracing scientific progress that benefits future generations.

This new phase of leadership underscores a simple truth: the FDA’s mission remains unwavering — to ensure that every drug on the market meets the highest standards of safety, quality, and efficacy.

Through a culture of integrity, innovation, and transparency, the U.S. Food and Drug Administration is preparing to lead America’s healthcare system into a safer, more effective, and technologically advanced future.